Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer May 21, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 8, 2026
OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates April 8, 2026
